ALSO NOTED: Novartis 4Q profit down 45%; Sanofi: Dr. Reddy's won't launch Plavix copy;

> Novartis' restructuring cut deeply into fourth-quarter profits, with a $444 million charge bringing earnings down to $931 million from $1.6 billion during the same quarter last year. Report

> Sanofi-Aventis said it's "highly unlikely" that India's Dr. Reddy's would launch a generic version of Sanofi's anti-clotting drug Plavix in the U.S. Report

> Japan's Eisai cleared an antitrust obstacle to its buyout of MGI Pharma; the $41 per share tender offer expires next week. Report

> The FDA warned today that two different drugs commonly referred to as EDTA--edetate disodium and edetate calcium disodium--should not be confused; both children and adults have died when given the wrong one. Report

> Pfizer has once again demonstrated its zeal for biotech, inking a $250 million deal to in-license the worldwide rights to an experimental osteoarthritis therapy under development at Germany's Scil Technology. Report

> Dr. Judah Folkman (photo)--whose work on angiogenesis spawned a new category of oncology drugs--died on Monday at the age of 74. Report

> Forecast: Biotech and pharmaceutical outsourcing will grow '08. Report

And Finally... First hormone therapy and now calcium supplements? What's a post-menopausal woman to do? Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.